Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Ionis Pharmaceuticals, Inc. (IONS)
Q1 2019 Earnings Conference Call
May 09, 2019, 11:30 ET
Wade Walke - VP, IR
Stanley Crooke - Founder, Chairman, CEO & President
Elizabeth Hougen - SVP, Finance & CFO
Brett Monia - Founder, COO, SVP, Translational Medicine & Director
Frank Bennett - SVP, Antisense Research
Conference Call Participants
Chad Messer - Needham & Company
Benjamin Burnett - Stifel, Nicolaus & Company
Rick Bienkowski - SVB Leerink
David Lebowitz - Morgan Stanley
Yanan Zhu - Wells Fargo Securities
Ritu Baral - Cowen and Company
Eliana Merle - Cantor Fitzgerald & Co.
Jessica Fye - JPMorgan Chase & Co.
I-Eh Jen - Laidlaw & Company
Good morning and welcome to the Ionis Pharmaceuticals Q1 2019 Financial Results Conference Call. As a reminder, this call is being recorded.
At this time, I would like to turn the call over to Wade Walke, Vice President, Investor Relations, to lead off the call. Please begin.
Previous Statements by IONS
» Ionis Pharmaceuticals, Inc. (IONS) CEO Stan Crooke on Q4 2018 Results - Earnings Call Transcript
» Ionis Pharmaceuticals, Inc. (IONS) CEO Stan Crooke on Q3 2018 Results - Earnings Call Transcript
» Ionis Pharmaceuticals, Inc. (IONS) CEO Stan Crooke on Q2 2018 Results - Earnings Call Transcript
We've also posted slides on our website that accompany our discussion today. With me on the call are Stan Crow, Chairman of the Board and Chief Executive Officer; Beth Hougen, Chief Financial Officer; Brett Monia, Chief Operating Officer; and joining us for Q&A will be Damien McDevitt, Chief Business Officer; and Frank Bennett, Senior Vice President of Research. I would like to draw your attention to Slide 3, which contains our forward-looking luggage statement. We'll begin - we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially.
I encourage you to consult the risk factors discussed in our SEC filings for additional detail. And with that, I'll turn the call over Stan.
Thanks, Wade, and good morning, everyone, and thank you for joining us on today's culture. We've had a busy week of various calls, so thanks. You may have noticed that this week, we unveiled our new brand. We think it better expresses our commitment to patients and the passion that we have for the science that creates life transforming of medicine.
It depicts and reinforces our culture, our technology, our business model and our position as a force for life. So now let's turn to Q1. We are off to a strong start, building on the momentum from last year. Our first quarter financial results significantly outperformed the first quarter of 2018 putting us well on track to achieve or perhaps more likely, potentially, exceed our 2019 financial guidance. Importantly, we achieved these strong financial results while investing aggressively and broadly in our business, including commercializing two medicines through early in next year and advancing our pipeline in technology.
SPINRAZA's blockbuster performance continued in the first quarter and continued to significantly contribute to our financial results. SPINRAZA has placed new ground in - of the - and is the established standard-of-care in the treatment of previously fatal and untreatable disease, SMA. Even today, 2-plus years after marketing, Biogen is continuing to generate new results and gain further understanding of SPINRAZA's benefited patients with all forms of SMA.
Recent clinical experience continues to demonstrate durability of benefit in patients with SMA, with some of these patients having been treated for over six years. With that, these results demonstrate that the benefit is not only durable, but is also increasing over time with the longer treatment resulting in even better benefit.
So in some, all of the information that we have about SPINRAZA leases here. That is that if we treat infants before they become symptomatic, most of those infants seem to develop like normal, healthy babies. So the earlier we treat, the better. And the longer we treat, the better. In addition, we are working with Biogen on follow-on medicines for SMA with the potential to offer the same exceptional benefit as SPINRAZA with less frequent dosing. We anticipate moving this new medicine into development soon.
Having completed the first full quarter of the TEGSEDI launch, we are encouraged by the initial sales and the feedback that we're getting from physicians and patients. Payers in the U.S. have been receptive to TEGSEDI, and we are also seeing good progress in expanding access in the EU.
WAYLIVRA is now our third antisense medicine approved in just over two years. We and Akcea are very pleased that the EU recognizes the value WAYLIVRA can bring to patients with FCS, and we look forward to making this new medicine available to FCS patients who desperately need it. Our pipeline of Phase III and near Phase III programs also achieved significant value-driving milestones in this quarter. Our medicines targeting SOD1-ALS and Huntington's disease entered Phase III development. And new data from ongoing clinical trials of - on these medicines continue to support potential of these medicines to improve the lives of patients with these fatal and debilitating diseases.
The next wave of medicines advancing toward Phase III this year include our LICA programs for LP(a)-driven cardiovascular disease and our LICA program for TTR amyloidosis. These two programs are examples of advances in our technology that have enhanced the performance of our medicines in the clinic and enabled us to broaden our pipeline to address, not only rare diseases but, many of the common diseases that affect millions of patients. Including these four medicines, we have at least 10 more medicines that have the potential to enter Phase III trials by the end of next year, and of course, that's a very exciting agenda for us and those patients.